| scholarly article | Q13442814 |
| P50 | author | Daniel J. Diekema | Q43292463 |
| Michael A. Pfaller | Q62070176 | ||
| Ronald N Jones | Q120908182 | ||
| P2093 | author name string | R J Hollis | |
| S A Messer | |||
| P2860 | cites work | Current and emerging azole antifungal agents | Q24550733 |
| A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients | Q28189320 | ||
| Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts | Q28368930 | ||
| In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods | Q28372129 | ||
| In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates | Q28378977 | ||
| In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species | Q28379025 | ||
| Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans | Q28379123 | ||
| In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) | Q28379217 | ||
| Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis | Q28379219 | ||
| In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents | Q33959506 | ||
| Quality control limits for broth microdilution susceptibility tests of ten antifungal agents | Q33969748 | ||
| Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans | Q33979304 | ||
| Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits | Q33981480 | ||
| Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia | Q34104748 | ||
| Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo | Q34335230 | ||
| Investigational antifungal agents. | Q34335243 | ||
| Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis | Q35823016 | ||
| Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te | Q36855581 | ||
| In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. | Q39651019 | ||
| Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. | Q39652915 | ||
| In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions | Q42547763 | ||
| A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis | Q43757967 | ||
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group | Q73102772 | ||
| Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp | Q73172089 | ||
| Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp | Q77474976 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluconazole | Q411478 |
| P304 | page(s) | 1068-1071 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates | |
| P478 | volume | 47 |
| Q33378325 | A first Portuguese epidemiological survey of fungaemia in a university hospital |
| Q43017233 | A multicentre study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients |
| Q46680628 | A pilot evaluation of pulse itraconazole vs. terbinafine for treatment of Candida toenail onychomycosis |
| Q34576400 | Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase |
| Q35170466 | Adhesion, biofilm formation, cell surface hydrophobicity, and antifungal planktonic susceptibility: relationship among Candida spp. |
| Q28552679 | An Optimized Lock Solution Containing Micafungin, Ethanol and Doxycycline Inhibits Candida albicans and Mixed C. albicans - Staphyloccoccus aureus Biofilms |
| Q42731827 | Anidulafungin and its role in candida infections |
| Q37274747 | Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates |
| Q30452376 | Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. |
| Q42408700 | Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1 |
| Q37115801 | Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing. |
| Q36311524 | Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review |
| Q34719843 | Candida guilliermondii fungemia in patients with hematologic malignancies |
| Q37794979 | Candida tropicalis in human disease |
| Q33851292 | Candidemia in patients with prolonged fever in Kashan, Iran |
| Q40404311 | Caspofungin activity against clinical isolates of fluconazole-resistant Candida |
| Q42948721 | Caspofungin in combination with amphotericin B against Candida parapsilosis |
| Q37118666 | Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis |
| Q33935389 | Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome |
| Q35537846 | Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis |
| Q35214623 | Caspofungin: the first in a new class of antifungal agents |
| Q37888750 | Caspofungin: when and how? The microbiologist's view |
| Q36925967 | Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance |
| Q41473569 | Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments |
| Q36011378 | Combination treatment of invasive fungal infections |
| Q36424929 | Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006 |
| Q42909935 | Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin |
| Q42561331 | Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. |
| Q34042198 | Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometry |
| Q37554055 | Current perspectives on echinocandin class drugs |
| Q41071178 | Determination of MICs of aminocandin for Candida spp. and filamentous fungi |
| Q36623050 | Developments in the treatment of candidiasis: more choices and new challenges |
| Q28264860 | Echinocandins in the management of invasive fungal infections, Part 2 |
| Q34019188 | Echinocandins: the newest class of antifungals |
| Q37858311 | Effect of traditional Chinese medicinal herbs on Candida spp. from patients with HIV/AIDS. |
| Q40667778 | Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani |
| Q42549201 | Effects of caspofungin against Candida guilliermondii and Candida parapsilosis |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q41825754 | First reported case of endocarditis caused by Candida dubliniensis |
| Q42131206 | Flow cytometry susceptibility testing for the antifungal caspofungin |
| Q41487959 | FsFKS1, the 1,3-beta-glucan synthase from the caspofungin-resistant fungus Fusarium solani |
| Q41039929 | Fungemia caused by Zygoascus hellenicus in an allogeneic stem cell transplant recipient |
| Q35718542 | Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. |
| Q38786061 | Future therapies targeted towards eliminating Candida biofilms and associated infections. |
| Q34431725 | Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions |
| Q42035300 | Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin |
| Q41024436 | In Vitro Activity of Caspofungin Against Fluconazole-Resistant Candida Species Isolated From Clinical Samples in Iran |
| Q41867739 | In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial |
| Q39459173 | In vitro activity of five antifungal agents against Candida albicans isolates, Sari, Iran |
| Q42834137 | In vitro activity of the lipopeptide PAL-Lys-Lys-NH2, alone and in combination with antifungal agents, against clinical isolates of Candida spp |
| Q41834480 | In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata |
| Q37598686 | In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies |
| Q34041745 | In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods |
| Q37568382 | Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state |
| Q36870777 | Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing |
| Q33981062 | Newer systemic antifungal agents : pharmacokinetics, safety and efficacy |
| Q36491819 | Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations |
| Q34510707 | Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility |
| Q40147093 | Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis |
| Q33232599 | Pharmacological advances in the treatment of invasive candidiasis |
| Q36176371 | Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin |
| Q25257510 | Presumptive identification of Candida species other than C. albicans, C. krusei, and C. tropicalis with the chromogenic medium CHROMagar Candida |
| Q36849595 | Resistance to echinocandin-class antifungal drugs |
| Q42051327 | Sensititre YeastOne caspofungin susceptibility testing of Candida clinical isolates: correlation with results of NCCLS M27-A2 multicenter study |
| Q37568916 | Sequential therapy with caspofungin and fluconazole for Candida albicans infection |
| Q39665961 | Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study |
| Q33938068 | Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates |
| Q41819710 | Strain typing and determination of population structure of Candida krusei by multilocus sequence typing. |
| Q37122826 | Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance |
| Q37159301 | Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV(+) patients to fluconazole, amphotericin B and Caspofungin. killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolate |
| Q36742397 | The echinocandins |
| Q46013189 | Time to positivity of blood culture can predict different Candida species instead of pathogen concentration in candidemia. |
| Q38053851 | Treatment of Candida famata bloodstream infections: case series and review of the literature. |
| Q58719932 | Trough concentration of itraconazole and its relationship with efficacy and safety: a systematic review and meta-analysis |
| Q57800919 | Unveiling the mechanisms of evolution towards fluconazole resistance of a clinical isolate: a transcriptomics approach |
| Q81533852 | [In vitro activity of the echinocandins. How should it be evaluated?] |
Search more.